Partner Linkage Tool for the Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase III: Research Teams
The Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase III: Research Teams Funding Opportunity is open to the diverse neurodegenerative diseases research community to carry out research projects that align with the three CCNA research themes (primary prevention, secondary prevention and treatment, quality of life) and the National Dementia Strategy (NDS).
The partnership tool aims to facilitate connections to support engagement throughout the research process. For example, it can help teams connect with researchers and knowledge users (KU)Footnote * to inform and strengthen the application development and planning of knowledge mobilization and dissemination strategies/activities.
To be included in the partnership tool, please complete this form. This form can be completed by researchers and KUs, including people with lived and living experience and decision makers, who are interested in sharing information and/or establishing collaborations for this funding opportunity. The information provided will be shared publicly in the below table, which will be updated regularly.
We encourage all the applicants for the CCNA Research Teams Funding Opportunity to complete this form to allow optimal exchange between all applicants.
Note that completing this form is voluntary as it is not a requirement of the application process and does not confer any advantages in the evaluation and funding of applications. Furthermore, potential applicants are not required to contact those who have chosen to make their information available through the Partnership tool.
By completing and submitting this form, you are consenting to having your responses posted, uneditedFootnote ** and in the language of submission (English or French). You may request to have your information edited or removed at any time by sending a request to BHCIA-SCTCV@cihr-irsc.gc.ca. Requests for edits or removal of information will be actioned regularly. If you have requested that your name and information be removed and then choose to be reinstated on the list, you will need to complete and submit the form again.
Should you have any questions regarding this form or the tool, please email BHCIA-SCTCV@cihr-irsc.gc.ca.
| Contact information | Location | Category | Interested in the Australia-Canada Indigenous Health Research priority area | Research Area | Expertise | Additional Information |
|---|---|---|---|---|---|---|
| Gu WenJie guwenjie1989@hotmail.com 13917589759 Melbourne University |
Victoria, Australia | Researcher Early career investigator Clinician researcher Healthcare Professional Practitioner Policy Maker/Decision Maker Person With Lived/Living Experience (of the disease, or families and care givers and/or care providers) |
Yes | Good | Good | Good |
| Peng Zhang peng.zhang.tjsh@gmail.com Acoustic Antidote |
Montreal, Quebec, Canada | Practitioner | Yes | I have been working on a musical/sound-based intervention for health effects. Since last year we have shifted our focus onto a modality for Alzheimer's patients. We propose a 3-fold method to tap into the pathways of "feeling safe and being cared for", musical chills, and the state of awe. During testing we noticed an increase in the gamma frequency brainwave activities in EEG monitoring. After encountering MIT Picower Institute's finding on the potential of 40Hz stimulation in reducing tau pathology, we would like to explore whether our method could deliver a similar effect through the gamma frequency that is induced inside the brain through musical stimuli. | Audio production, spatial sound experience, EEG, gamma frequency | We would like to collaborate with researchers on this proposed treatment modality in the areas of research design, data collection and analysis. We would like to explore both the validity of the method and the mechanism of its actions. For this, research grade EEG measurement and brain imaging data will be necessary to observe the evolution of pathology structure. We remain flexible with the proposed method and is open to discussion and iteration in the modality. |
| Peter Malouf peter.malouf@unsw.edu.au University of New South Wales |
New South Wales, Australia | Researcher | Yes | Indigenous Health, Alcohol Abuse, Health Systems | Mixed methods research, health system design, and policy development | Collaboration with partners in Canada to build an Indigenous specific AOD network to support comparative research opportunities relating to interventions, treatment and recovery. |
| Jeffrey Henderson University of Toronto |
Ontario, Canada | Researcher | Maybe | Primary Prevention, Secondary Prevention/Treatment | The laboratory’s research focuses on molecular mechanisms governing programmed cell death (PCD) in the mammalian brain and stem cells under both normal and injury states such as stroke and neurodegenerative diseases such as Alzheimer’s. Recently in conjunction with the laboratories of Drs. S. Wu and P. Fraser, we have sought to modify glial neuro-inflammatory response and its subsequent effects neuronal PCD using nanoparticle-mediated gene modification in murine models of Alzheimer’s disease. Through a better understanding of the molecular mechanisms regulating the aberrant activation of PCD seen in both Alzheimer’s and natural aging, we aim to identify small molecule therapeutics to prevent neuronal loss. | Our team has for several years worked to develop multi-modal in vivo, ex vivo and in vitro real-time approaches to examining the varied cellular and molecular mechanisms mediating novel forms of PCD. These approaches have focused largely on real-time optical methods to analyze cell-cell communication and protein interactions of interest. Protein modifications are supported through standard transgenic and gene modification methods such as CRISPR. In the present funding opportunity we seek to both extend elements of analysis, as well as optimize siRNA/shRNA approaches. |
| Richard Camicioli University of Alberta rcamicio@ualberta.ca |
Alberta, Canada | Researcher | No | Diagnosis, biomarkers and treatment (Secondary prevention/treatment) of Lewy body disorders. Our goal is to facilitate early diagnosis and prognostic prediction of Lewy body disorders to better inform families and patients regarding prognosis. These markers are aimed at helping track disease progression and could potential accelerated clinical trials and better understand the biology of disease. Our second major goal is to determine the feasibility of lifestyle interventions in this group of patients at-risk for rapid decline. | Imaging, Dementia diagnosis Parkinson's disease and Lewy body disease managment | Families with Lewy body disorders frequently ask about prognosis which is not well established early in the course of diesase. In addition clinicians ofen require more information in managing these disrorders. These are examples of knowledge users. |
- Date modified: